Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Account Payables (2016 - 2026)

Corvus Pharmaceuticals' Change in Account Payables history spans 12 years, with the latest figure at $2.2 million for Q1 2026.

  • Quarterly Change in Account Payables rose 273.16% to $2.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Mar 2026, up 1225.91% year-over-year, with the annual reading at -$91000.0 for FY2025, 108.61% down from the prior year.
  • Change in Account Payables came in at $2.2 million for Q1 2026, up from $517000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.2 million in Q1 2026 to a low of -$2.3 million in Q4 2022.
  • The 5-year median for Change in Account Payables is $210000.0 (2022), against an average of $184235.3.
  • The largest YoY upside for Change in Account Payables was 561.87% in 2025 against a maximum downside of 1616.67% in 2025.
  • Corvus Pharmaceuticals' Change in Account Payables stood at -$2.3 million in 2022, then surged by 105.38% to $121000.0 in 2023, then skyrocketed by 485.95% to $709000.0 in 2024, then dropped by 27.08% to $517000.0 in 2025, then surged by 326.69% to $2.2 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Change in Account Payables are $2.2 million (Q1 2026), $517000.0 (Q4 2025), and -$1.2 million (Q3 2025).